GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Holy Stone Healthcare Co 4194.TWO · TWD

N/A · Taipei Exchange · 🇹🇼 Taiwan

Compare

6.11

+0.16%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Holy Stone Healthcare Co

Its shares trade on Taipei Exchange under the ticker 4194.TWO. It has been listed since 13 December 2013. In the fiscal year to 31 December 2024, it reported revenue of TWD 118.8m and a net loss of TWD 183.5m. At that date it held total assets of TWD 353.0m and shareholders' equity of TWD 294.1m.

Holy Stone Healthcare Co., Ltd. engages in the research, development and manufacture of hyaluronic acid drugs and medical devices. The company is headquartered in Taipei City, Taipei. The company went IPO on 2013-12-13. The firm's main products include latent tuberculosis infection test reagents, Ostenil branded joint cavity injection and other medical equipment. The firm is also involved in the manufacture of western medicines, as well as the research and development of new drugs and new medical materials. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
13 Dec 2013
Employees
35

Leadership

Pay as last reported

  • Mr. Jing-Rong TangChairman of the Board
  • Qinghua YangGeneral Manager, Director, since 2014
  • Guoye XuDeputy General Manager, DirectorTWD 500,000
  • Yuling LiuHead of Finance & Accounting
  • Jialong HouDirector
  • Chien Jung HuangDirector
  • Mr. Hui-Bang YehDirector
  • Mr. Chi-Ming ChenIndependent Director
  • Ms. Zhaoyuan HuangIndependent Director
  • Mr. Kao-Chung TsaiIndependent Director
  • Yuzhi ChenIR Contact Officer, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Hyaluronic acid drugs and medical devices are key products in the Health Care sector.
  • Ostenil branded joint cavity injection is a leading medical equipment product.
  • Latent tuberculosis infection test reagents are a core product for domestic market distribution.

Weaknesses

  • Limited employee count of 35 restricts R&D capacity and market reach.
  • IPO date of 13 December 2013 indicates a relatively young company.
  • Domestic market focus may limit international expansion opportunities.

Opportunities

  • Growing demand for hyaluronic acid drugs in the Health Care sector.
  • Expansion into overseas markets for medical equipment distribution.
  • New drug and medical material R&D could drive future growth.

Threats

  • Competition from established medical device manufacturers in Taiwan.
  • Regulatory changes in the Health Care sector could impact product approvals.
  • Overreliance on domestic market may expose the company to local economic fluctuations.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.